There are 11 clinical trials for melanoma of unknown primary, of which 9 are open and 2 are completed or closed. Of the trials that contain melanoma of unknown primary as an inclusion criterion, 1 is phase 1 (1 open), 9 are phase 2 (7 open), and 1 is phase 3 (1 open).

BRAF is the most frequent gene inclusion criterion for melanoma of unknown primary clinical trials [3].

Nivolumab, binimetinib, and dabrafenib are the most common interventions in melanoma of unknown primary clinical trials.